Nwankwo Henry, Mason James, Underwood Martin, Parsons Helen, Haque Aminul, Torgerson David, Modi Chetan, Kearney Rebecca S
Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
York Clinical Trials Unit, University of York, York, UK.
Bone Jt Open. 2025 May 5;6(5):535-543. doi: 10.1302/2633-1462.65.BJO-2024-0246.R1.
We aimed to conduct a cost-utility analysis comparing one session of advice, supporting materials, and option to self-refer to physiotherapy with the same advice and materials, plus an additional programme of physiotherapy for people with a first-time, traumatic anterior shoulder dislocation.
We conducted an economic evaluation within a randomized controlled trial from the UK NHS and personal social services (PSS) perspective. Resources used, and health-related quality of life information, were collected as part of the Acute Rehabilitation following Traumatic anterior shoulder dISlocAtioN (ARTISAN) randomized controlled trial over a 12-month period using patient-completed questionnaires. Incremental costs and quality-adjusted life-years (QALYs) accrued over the follow-up period were calculated and expressed as the incremental cost-effectiveness ratio (ICER). Estimate uncertainty was explored by bootstrapping and graphically displayed on the ICER plane. Net monetary benefits, probability of cost-effectiveness, and expected value of perfect information were explored at a range of willingness-to-pay thresholds and visualized graphically.
Over a 12-month time horizon, incremental costs were £64 (95% CI -61 to 191) and incremental QALYs were 0.019 (95% CI -0.0005 to 0.0375) for the additional programme of physiotherapy. The ICER was £3,373/QALY, suggesting that the programme is cost-effective, although the primary outcome (Oxford Shoulder Instability Score) found little difference six months after a shoulder dislocation. The probability of being cost-effective at a willingness-to-pay threshold of £30,000 per QALY is 95%. Findings need to interpreted with caution given the high rates of missing data at 12 months, due to the final 12-month follow-up being curtailed during the trial. However, the range of sensitivity analyses supports the base case findings.
The within-trial economic evaluation found that the additional physiotherapy programme is likely to be cost-effective. However, given the small and imprecise health gains, the best use of scarce physiotherapy resources needs careful consideration given other current demands on services.
我们旨在进行一项成本效用分析,比较为首次创伤性前肩关节脱位患者提供一次建议、辅助材料以及自我转诊至物理治疗的选项,与提供相同建议和材料外加额外物理治疗方案的效果。
我们从英国国民健康服务体系(NHS)和个人社会服务(PSS)的角度,在一项随机对照试验中进行了经济评估。作为创伤性前肩关节脱位急性康复(ARTISAN)随机对照试验的一部分,在12个月期间使用患者填写的问卷收集了所使用的资源以及与健康相关的生活质量信息。计算了随访期间产生的增量成本和质量调整生命年(QALY),并表示为增量成本效益比(ICER)。通过自举法探讨估计的不确定性,并在ICER平面上以图形方式显示。在一系列支付意愿阈值下探讨了净货币效益、成本效益概率和完美信息的期望值,并以图形方式可视化。
在12个月的时间范围内,额外物理治疗方案的增量成本为64英镑(95%CI -61至191),增量QALY为0.019(95%CI -0.0005至0.0375)。ICER为3373英镑/QALY,这表明该方案具有成本效益,尽管主要结局(牛津肩关节不稳定评分)显示肩关节脱位六个月后差异不大。在每QALY支付意愿阈值为30000英镑时具有成本效益的概率为95%。鉴于12个月时缺失数据的比例较高,由于试验期间最后12个月的随访被缩短,研究结果需要谨慎解释。然而,敏感性分析的范围支持了基础案例的结果。
试验中的经济评估发现,额外的物理治疗方案可能具有成本效益。然而,鉴于健康收益较小且不精确,考虑到当前对服务的其他需求,需要仔细考虑如何最佳利用稀缺的物理治疗资源。